Mineralys Therapeutics (MLYS) earnings

Healthcare · Biotechnology · Market cap $2.0B

In the quarter ended June 2026, Mineralys Therapeutics had revenue of —, and diluted EPS of -2.85.

On August 11, 2026 it reported EPS of -2.85 against an estimate of -0.57 (missed).

The next report is expected on Monday, November 9, 2026, with EPS expected around -0.53.

Report dates

ReportDateTimeEPS estimateEPS reported
NextMon Nov 9, 2026 — -0.53 —
LastTue Aug 11, 2026 — -0.57 -2.85

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 12 quarters from Mineralys Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2026— — -2.85 — — 2026-08-11
Mar 31, 2026— — -0.47 — — 2026-05-06
Dec 31, 2025— — — — — 2026-03-12
Sep 30, 2025— — -0.52 — — 2025-11-10
Jun 30, 2025— — -0.66 — — 2025-08-12
Mar 31, 2025— — -0.79 — — 2025-05-12
Dec 31, 2024— — — — — 2025-02-12
Sep 30, 2024— — -1.13 — — 2024-11-12
Jun 30, 2024— — -0.83 — — 2024-08-13
Mar 31, 2024— — -0.70 — — 2024-05-09
Dec 31, 2023— — — — — 2024-03-21
Sep 30, 2023— — -0.57 — — 2023-11-07
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MLYS.
Open MLYS in Investingly

Questions

When does Mineralys Therapeutics report earnings?

Mineralys Therapeutics's next earnings report is expected on November 9, 2026.

How did Mineralys Therapeutics do last quarter?

In the quarter ended June 2026, Mineralys Therapeutics had revenue of —, and diluted EPS of -2.85.

From Mineralys Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.